$MSFT — Tech Momentum Meets Microcap Turmoil: Microsoft Rally and Anthropic Permission Contrast with Sharp Small‑Cap Selloffs

Earnings Surprises & Forecasts: Using Analyst Estimates in Your Analysis

Earnings Surprises & Forecasts: Using Analyst Estimates in Your Analysis

$MSFT — Tech Momentum Meets Microcap Turmoil: Microsoft Rally and Anthropic Permission Contrast with Sharp Small‑Cap Selloffs

$MSFT — Microsoft jumped 5.71% to $372.97 on heavy volume as optimism around large-cap tech momentum re-emerged, while the Trump administration’s conditional approval for Anthropic’s Mythos rollout adds a measured AI catalyst. At the same time, steep, high‑participation declines in several small-cap names (CELZ, RNWWW, GDC) underscore acute liquidity and idiosyncratic risk across the market.

$MSFT $ORCL — AI Buzz and Structural Shifts Steal the Spotlight as Microcaps Scream: Microsoft, Oracle, Cboe and a Weekend of Wild Volume

$MSFT $ORCL — Renewed AI enthusiasm lifted Microsoft, while Oracle’s cash-flow and debt story dragged shares into their worst week since 2001. At the same time Cboe launched binary Mini‑S&P products and retail-driven microcaps posted extreme spikes and collapses—heavy volume into the holiday weekend raises liquidity and catalyst risk ahead of Monday.

$MSOS — Cannabis Sector Eyes DEA Rescheduling - Jun 27

$MSOS — $MSOS — Cannabis Sector Eyes DEA Rescheduling - Jun 27

Earnings Momentum Meets Regulatory Drag: Q1 Gains, AI Supply-Chain Interest, and Biotech Execution Risk Shape Today's Tape

A batch of Q1-driven rallies in consumer and regional-bank names sat alongside renewed AI supply-chain interest and a biotech regulatory setback. Data today points to momentum-fueled re-ratings, growing focus on execution risk, and a bifurcated market where valuation discipline increasingly matters.